Compared to individual STK11, KEAP1, or TP53 mutations, comutation of KRAS and STK11, KEAP1, or TP53 was associated with worse or better clinical responses to ICIs in patients with NSCLC [7, 8, 13]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.